Skip to main content

Advertisement

SpringerLink
Log in

Biologic agents in the management of inflammatory eye diseases

  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Biologics are a new class of drugs that comprise recombinant cytokines and monoclonal antibodies directed against selected cell-surface markers. They include the tumor necrosis factor-α inhibitors infliximab, etanercept, and adalimumab; the antilymphocyte drugs rituximab and alemtuzumab; the interleukin-2 receptor blocker daclizumab; and recombinant interferon-α. This article reviews the rationale and current evidence for their use in uveitis, scleritis, and orbital inflammation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. International Study Group for Behcet’s Disease: Criteria for diagnosis of Behçet’s disease. Lancet 1990, 335:1078–1080.

    Google Scholar 

  2. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al.: Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 2001, 358:295–296.

    Article  PubMed  CAS  Google Scholar 

  3. Ohno S, Nakamura S, Hori S, et al.: Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol 2004, 31:1362–1368.

    PubMed  CAS  Google Scholar 

  4. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al.: Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 2004, 140:404–406.

    PubMed  CAS  Google Scholar 

  5. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al.: Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease. Arthritis Rheum 2005, 52:2478–2484.

    Article  PubMed  CAS  Google Scholar 

  6. Mushtaq B, Saeed T, Situnayake RD, Murray PI: Adalimumab for sight threatening uveitis in Behçet’s disease. Eye 2007, 21:824–825.

    Article  PubMed  CAS  Google Scholar 

  7. van Laar JAM, Missoten T, van Daele PLA, et al.: Adalimumab, a new modality for Behçet’s disease? Ann Rheum 2007, 66:565–566.

    Article  CAS  Google Scholar 

  8. Saurenmann RK, Levin AV, Rose JB, et al.: Tumour necrosis factor α inhibitors in the treatment of childhood uveitis. Rheumatology 2006, 45:982–989.

    Article  PubMed  CAS  Google Scholar 

  9. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M: Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol 2006, 244:1692–1695.

    Article  PubMed  CAS  Google Scholar 

  10. Bodaghi B, Gendron G, Bertrand Wechsler B, et al.: Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007, 91:335–339.

    Article  PubMed  Google Scholar 

  11. Kotter I, Zierhut M, Eckstein AK, et al.: Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003, 87:423–431.

    Article  PubMed  CAS  Google Scholar 

  12. Lockwood CM, Hale G, Waldman H, Jayne DRW: Remission induction in Behçet’s disease following lymphocyte depletion by the anti-CD 52 antibody CAMPATH 1-H. Rheumatology 2003, 42:1539–1544.

    Article  PubMed  CAS  Google Scholar 

  13. Buggage RR, Levy-Clarke G, Sen HN, et al.: A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet’s disease. Ocul Immunol Inflam 2007, 15:63–70.

    Article  CAS  Google Scholar 

  14. Nussenblatt RB, Fortin E, Schiffman R, et al.: Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 1999, 96:7462–7466.

    Article  PubMed  CAS  Google Scholar 

  15. Papaliodis GN, Chu D, Foster CS: Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003, 110:786–789.

    Article  PubMed  Google Scholar 

  16. Nussenblat RB, Peterson JS, Foster CS, et al.: Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis. Ophthalmology 2005, 112:764–770.

    Article  Google Scholar 

  17. Ziegenhagen MW, Rothe ME, Zissel G, Muller-Quernheim J: Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002, 19:185–190.

    PubMed  Google Scholar 

  18. Baughman RP, Drent M, Kavuru M, et al.: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Resp Crit Care Med 2006, 174:795–802.

    Article  PubMed  CAS  Google Scholar 

  19. Doty JD, Mazur JE, Marc A, Judson MA: Treatment of sarcoidosis with infliximab. Chest 2005, 127:1064–1071.

    Article  PubMed  CAS  Google Scholar 

  20. Baughman RP, Lower EE, Bradley DA, et al.: Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005, 128:1062–1147.

    Article  PubMed  Google Scholar 

  21. Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN: Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 2006, 25:596–597.

    Article  PubMed  Google Scholar 

  22. Gallagher M, Quinones K, Cervantes-Castaneda RE, et al.: Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007, 91:1341–1344.

    Article  PubMed  Google Scholar 

  23. Petty RE, Southwood TR, Baum J, et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 1998, 25:1991–1994.

    PubMed  CAS  Google Scholar 

  24. Carvounis PE, Herman DC, Cha S, Burke JP: Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol 2006, 244:281–290.

    Article  PubMed  Google Scholar 

  25. Reiff A, Takei S, Sadeghi S, et al.: Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001, 44:1411–1415.

    Article  PubMed  CAS  Google Scholar 

  26. Smith JA, Thompson DJS, Whitcup SM, et al.: A randomized, placebo controlled, double masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005, 53:18–23.

    Article  PubMed  CAS  Google Scholar 

  27. Quartier P, Taupin P, Bourdeaut F, et al.: Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003, 48:1093–1101.

    Article  PubMed  CAS  Google Scholar 

  28. Lovell DJ, Giannini EH, Reiff A, et al.; Pediatric Rheumatology Collaborative Study Group: Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000, 342:763–769.

    Article  PubMed  CAS  Google Scholar 

  29. Tynjälä P, Lindahl P, Honkanen V, et al.: Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007, 66:548–550.

    Article  PubMed  CAS  Google Scholar 

  30. Kahn P, Weis M, Imundo LF, Levy DM: Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006, 113:860–864.

    Article  PubMed  Google Scholar 

  31. Biester S, Deuter C, Michels H, et al.: Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007, 91:319–324.

    Article  PubMed  Google Scholar 

  32. Vazquez-Cobian LB, Flynn T, Lehman TJA: Adalimumab therapy for childhood uveitis. J Pediatr 2006, 149:572–575.

    Article  PubMed  CAS  Google Scholar 

  33. Braun J, Sieper J: Biological therapies in the spondyloarthritides—the current state. Rheumatology 2004, 43:1072–1084.

    Article  PubMed  CAS  Google Scholar 

  34. Braun J, Baraliakos X, Listing J, Sieper J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005, 52:2447–2451.

    Article  PubMed  CAS  Google Scholar 

  35. El-Shabrawi Y, Hermann J: Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002, 109:2342–2346.

    Article  PubMed  Google Scholar 

  36. Sobrin L, Kim EC, Christen W, et al.: Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007, 125:895–900.

    Article  PubMed  CAS  Google Scholar 

  37. Van Rijthoven AW, Jacobs JW: Seronegative spondylarthropathy: variable manifestations, common characteristics. Ned Tijdschr Geneeskd 2007, 151:1377–1381.

    PubMed  Google Scholar 

  38. Taban M, Dupps WJ, Mandel B, Perez V: Etanercept (Enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 2006, 14:145–150.

    Article  PubMed  Google Scholar 

  39. Lim LL, Fraunfelder FW, Rosenbaum JT: Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007, 56:3248–3252.

    Article  PubMed  CAS  Google Scholar 

  40. Suhler EB, Smith JR, Wertheim MS, et al.: A prospective trial of infliximab therapy for refractory uveitis. Arch Ophthalmol 2005, 123:903–912.

    Article  PubMed  CAS  Google Scholar 

  41. Lindstedt EW, Baarsma GS, Kuijpers RWAM, van Hagen PM: Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005, 89:533–536.

    Article  PubMed  CAS  Google Scholar 

  42. Ardoin SP, Kredich D, Rabinovich E, et al.: Infliximab to treat chronic noninfectious uveitis in children: Retrospective case series with long-term follow-up. Am J Ophthalmol 2007, 144:844–849.

    Article  PubMed  CAS  Google Scholar 

  43. Foster CS, Tufail F, Waheed NK, et al.: Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003, 121:437–440.

    Article  PubMed  CAS  Google Scholar 

  44. Plskova J, Greiner K, Forrester JV: Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007, 144:55–61.

    Article  PubMed  CAS  Google Scholar 

  45. Deuter CE, Koetter I, Guenaydin I, et al.: Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 2006, 26:786–791.

    Article  PubMed  Google Scholar 

  46. Dick AD, Meyer P, James T, et al.: Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000, 84:107–109.

    Article  PubMed  CAS  Google Scholar 

  47. Tappeiner C, Heinz C, Specker C, Heilinghaus A: Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007, 39:184–186.

    Article  PubMed  CAS  Google Scholar 

  48. Breedveld FC, Emery P, Keystone E, et al.: Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004, 63:149–155.

    Article  PubMed  CAS  Google Scholar 

  49. Smith JR, Levinson RD, Holland GN, et al.: Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Care Res 2001, 45:252–257.

    Article  CAS  Google Scholar 

  50. Hernandez-Illas M, Tozman E, Fulcher SFA, et al.: Recombinant human tumor necrosis factor receptor Fc fusion protein (etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration. Eye Contact Lens 2004, 30:2–5.

    Article  PubMed  Google Scholar 

  51. Murphy CC, Ayliffe WH, Booth A, et al.: Tumor necrosis factor blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004, 111:352–356.

    Article  PubMed  Google Scholar 

  52. Galor A, Perez VL, Hammel JP, Lowder CY: Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006, 113:2317–2323.

    Article  PubMed  Google Scholar 

  53. Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 2005, 352:351–361.

    Article  Google Scholar 

  54. Cheung CM, Murray PI, Savage CO: Successful treatment of Wegener’s granulomatosis associated scleritis with rituximab. Br J Ophthalmol 2005, 89:1542.

    Article  PubMed  CAS  Google Scholar 

  55. Ahmadi-Simab K, Lamprecht P, Nolle B, et al.: Successful treatment of refractory anterior scleritis in primary Sjögren’s syndrome with rituximab. Ann Rheum Dis 2005, 64:1087.

    Article  PubMed  CAS  Google Scholar 

  56. Paridaens D, van den Bosch WA, van der Loos TL, et al.: The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye 2005, 19:1286–1289.

    Article  PubMed  CAS  Google Scholar 

  57. Durrani OM, Reuser TQ, Murray PI: Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit 2005, 24:117–119.

    Article  PubMed  CAS  Google Scholar 

  58. Garrity JA, Coleman AW, Matteson EL, et al.: Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am J Ophthalmol 2004, 138:925–930.

    Article  PubMed  CAS  Google Scholar 

  59. Adams AB, Kazim M, Lehman TJA: Treatment of orbital myositis with adalimumab (Humira). J Rheumatol 2005, 32:374–375.

    Google Scholar 

  60. Salvi M, Vannucchi G, Campi I, et al.: Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007, 156:33–40.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Macular Research Unit, Centre for Eye Research Australia, University of Melbourne, 32 Gisborne Street, East Melbourne, Victoria, 3002, Australia

    Lyndell Lim

Authors
  1. Kira Michalova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lyndell Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lyndell Lim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Michalova, K., Lim, L. Biologic agents in the management of inflammatory eye diseases. Curr Allergy Asthma Rep 8, 339–347 (2008). https://doi.org/10.1007/s11882-008-0054-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-008-0054-2

Keywords

Search

Navigation